These results correspond to the data from the HypoAna trial, where the RRR for nocturnal non-severe hypoglycemia was 39% during treatment with insulin analogs, translating into an ARR of 4.2 E/PY (Agesen et al., 2016). The gene discussed is INS; the disease is Hypoglycemia.